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Protein Expression and Purification 
Menin (residues 2-610 containing a deletion from 460-519) was cloned into an N-terminally His6-Sumo tagged expression construct. 
Transformed cells were grown in Terrific Broth at 37 °C to an O.D.600 of 1.0, then induced with 0.4 mM IPTG overnight at 20 °C. Freeze-
thawed cell pellets were resuspended in 25 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM DTT with protease inhibitors, then sonicated. 
The supernatant was cleared of debris through centrifugation. The supernatant was incubated for 1 h at 4 °C with Ni-NTA (Qiagen) 
equilibrated with 25 mM Tris-HCl, pH 8.0 and 150 mM NaCl (Buffer A). The Ni-NTA was washed extensively with Buffer A and the 
protein eluded with Buffer A plus 250 mM imidazole. Eluent was dialyzed overnight at 4 °C in Buffer A containing 1 mM DTT and Sumo 
protease for tag cleavage. The cleaved protein was reapplied to the Ni-NTA column to remove the His6-Sumo tag, then concentrated 
and loaded onto a Superdex 200 (GE Healthcare) size exclusion column equilibrated with Buffer A and 5 mM DTT. The purified protein 
was concentrated to 25 mg/mL and stored at -80 °C. 
Fluorescence Polarization (FP)-Based Binding Assay 
We used the assay conditions described previously.[1]  
Cell Growth Inhibition Assay 
MV4;11, K562, HL-60, and RS4;11 cells were purchased from ATCC and SEM, MOLM-13, MOLM-14, MOLM-16, SKM-1, and MONO-
MAC-6 were purchased from DSMZ. Cells were cultured in either Iscove's Modified Dulbecco's Medium or  RPMI 1640 medium (ATCC) 
supplemented with 10% fetal bovine serum and 100 U/L penicillin-streptomycin and incubated at 37 °C under 5% CO2, according to 
the cell supplier’s instructions.  
For cell growth experiments, cells were seeded into 96-well plates at a density of 100,000 cells per well (4-day testing) or 2,000-3,000 
cells per well (7-day testing) in 200 µL culture medium and treated with either vehicle control (DMSO, 0.1%) or compounds for indicated 
time. At the end of an experiment, Cell Count Kit (Dojindo) was used to measure cell viability. Data were analyzed using PRISM 
software. 
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Detailed Method of Modeling of Compounds 6 and 7 Bound to Menin 
The crystal structure of the complex between Menin and (R)-MIV-6 (PDB ID: 4OG8[2]) was used to build the binding models of designed 
molecules with Menin. Menin protein from the crystal structure was extracted and the missing side chains in Menin were added using 
the MOE program.[3] The “protonate 3D” module in MOE was then used to add hydrogen atoms to Menin at the physiological condition. 
The designed compounds were prepared using the MOE program and the GOLD program[4] (version 5.1) was used to perform the 
docking simulations. The binding site was centered at Y323 in Menin with a radius of 15 Å. Default parameters for the genetic algorithm 
(GA) run were adopted. The selection of docking poses were assessed by GoldScore (the fitness function) implemented in Gold 5.1. 
The top ranked conformations based on GoldScore were analyzed and compare with the available crystal structures to determine the 
binding modes of the compounds. Figures were prepared using the PyMOL program. 
Figure S1. a), b) Modeling of compounds 6 or 7 bound to Menin. (Protein pocket is shown in gray cartoon model and the residues close to inhibitor are highlighted 
in stick model. Inhibitors are shown in stick representation with yellow carbon atoms. Oxygen atoms are shown in red; nitrogens in blue and sulfurs in yellow. Dashed 
lines depict hydrogen bonds.) 
Detailed Method of Mass-spectroscopic Analysis of Human Menin Protein Incubated 
with Menin Inhibitors 
Samples of menin (25 mg/mL in 25 mM T ris 8.0, 150 mM NaCl and 5mM DTT) were incubated with compounds 8, 9 or 10 in a protein 
to compound molar ratio of 1: 1.2 for 1 h or overnight at 4 °C. Following incubation, the sample was diluted to 1 mg/mL with water.  0.1 
mL of each sample was applied to a reverse phase HPLC column (Phenomenex Aeris widepore C4 column 3.6 μM, 50 × 2.10 mm) at 
a flow rate of 0.5 mL/min in H2O with 0.2% (v/v) formic acid. Protein was eluted using a gradient of 5-100% acetonitrile with 0.2% (v/v) 
formic acid over 4 minutes. LC-MS experiment (Agilent Q-TOF 6545) was carried out under the following conditions: fragmentor voltage, 
300 V; skimmer voltage, 75 V; nozzle voltage, 100 V; sheath gas temperature, 350 °C; drying gas temperature, 325 °C. MassHunter 
Qualitative Analysis Software (Agilent) was used to analyze the data. Intact protein masses were obtained using the maximum entropy 
deconvolution algorithm. 
Table S1. Mass-spectrometry of Menin Incubated with or without Menin Inhibitors. 
ID Calculated exact mass Incubation time Analyzed exact mass Difference in mass Notes 
Apo Menin 60992.12 
1 h 60992.34   
overnight 60991.91   
8 677.3 
1 h 61669.64 677.3 Only about 50% incorporation after 1 h 
overnight 61669.42 677.51 100% incorporation of compound overnight 
9 679.32 
1 h 60991.76   No binding 
overnight 60991.56   No binding 
10 734.36 
1 h 61726.83 734.49 more than 95% incorporation of compound after 1 h 
overnight 61726.58 734.67 100% incorporation of compound after overnight 
Compound 7
b
C329
L371 V367
F238
M278
Y276
Compound 6
C329
L371 V367
F238
M278 Y276
W341 W341
6.7 Å
a
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Mass-spectra 
Mass of Apo Menin after 1 h: 
 
 
 
Mass of Apo Menin overnight: 
 
 
 
Mass of Menin with compound 8 after 1h: 
 
 
 
Mass of Menin with compound 8 overnight: 
 
 
 
 
 
Apo Mass = 60992.12 Da 
Apo Mass = 60991.91 Da 
within the +/-1 Da error 
Mass Difference = 677.30 Da 
>50% incorporation after 1 hr 
Mass Difference = 677.51 Da 
100% incorporation overnight 
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Mass of Menin with compound 9 after 1h: 
 
 
 
Mass of Menin compound 9 overnight: 
 
 
 
Mass of Menin with compound 10 after 1 h: 
 
 
 
Mass of Menin with compound 10 overnight: 
 
 
 
 
 
 
 
 
 
No covalent binding within 1 hr 
No covalent binding overnight 
Mass Difference = 734.49 Da 
~95% incorporation with 1 h 
Mass Difference = 734.67 Da 
100% incorporation overnight 
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Association/dissociation Kinetic Assay Using Octet Red 
Biotinylation: 
Purified recombinant menin protein was biotinylated using the Thermo EZ-Link long-chain biotinylation reagent. Menin protein and 
biotinylation reagent were mixed with 1:1 molar ratio in PBS at 4 °C. This reaction mixture was incubated at 4 °C for 2 h. Reaction 
mixture was then dialyzed using Fishersci 10K MWCO dialysis cassettes to remove unreacted biotinylation reagent. 
Bio-Layer Interferometry (BLI) binding assay: 
Bio-Layer Interferometry (BLI) binding assays were performed in 96-well microplates at room temperature with continuous 1000 rpm 
shaking using the Octet Red 96 system (Fortebio, Menlo Park, CA, USA). PBS with 0.1% BSA, 0.01% Tween-20 and 2% DMSO was 
used as the assay buffer. Biotinylated menin protein was tethered on Super Streptavidin (SSA) biosensors (ForteBio) by dipping sensors 
into 200 µL per well 10 µg/mL protein solutions. Average saturation response level of 8-10 nm was achieved in 20 minutes. The 
measurement processes were all under computer control. Program procedures were established as follows: For the initial step, 
biosensors were washed in assay buffer for 60 sec to form a baseline; the biosensors labeled with biotin-Menin were exposed to 100 
nM compounds for association, and were monitored for 1200 sec; and then, the biosensors were moved back into assay buffer to 
disassociate for another 1800 sec. Data were fit globally and generated automatically by Octet User software (version 9.0; Fortebio). 
 
 
 
 
 
 
 
 
Figure S2. Association/dissociation kinetics of compounds for menin determined by Octet. Association time was 1200 s and dissociation time was 1800 s. 
Compounds 8 and 10 do not show obvious dissociation, while compound 9 shows dissociation. 
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Detailed Method for X-ray Crystallography Determination of Compound 10 Bound to 
Menin 
Prior to crystallization, Menin (25 mg/mL in 25 mM Tris 8.0, 150 mM NaCl and 5mM DTT) was incubated with compound 10 in a protein 
to compound ratio of 1:1.2 at 4 °C for 24 hr. Crystals grew in drops containing 1 µL of complex and 1 µL of well solution (1.96 M NaCl, 
89 mM Bis-Tris pH 6.8, 0.178 M MgCl2 and 10.7 mM Pr Acetate). Crystals were cryoprotected by progressively soaking crystals in well 
solution with increasingly higher amounts of sodium formate (1 M - 5 M in 1M steps). Diffraction data were collected on a Mar300 
detector at the Advanced Photon Source LS-CAT 21-ID-G beamline at Argonne National Laboratory with a wavelength of 0.9786 Å 
and processed with HKL2000[5]. The structure of menin bound to compound 10  was solved by molecular replacement (Molrep[6]) using 
the apo menin structure (PDB ID 3U84) as the search model. The menin-10  structure went through iterative rounds of electron density 
fitting and structural refinement using Coot[7] and Buster[8], respectively. The coordinates and restraint files for the ligand were created 
from smiles in Grade4 with the mogul+qm option. The initial Fo-Fc electron density map showed the presence of compound 10 in the 
active site covalently bound to C329 (Figure S3). The following regions were disordered in the structure: 71-73, 386-401, 528-547 and 
582-610. Data collection and structural refinement statistics are shown in Table S2. 
Table S2. Crystallography Data Collection and Refinement Statistics. 
Data Collection  Menin-10 
PDB ID 6B41 
Space Group I41 
Unit Cell (Å) a = b =153.920 c = 81.618 
===90°
Wavelength (Å) 0.9786 
Resolution (Å)1 2.61 (2.61—2.66) 
Rmerge2 0.102 (0.665) 
<I/I>3 10 (2) 
Completeness (%)4 99.8 (96.6) 
Redundancy 12.1 (11.0) 
 
Refinement  
 
Resolution (Å) 2.61 
R-Factor5 0.208 
Rfree6 0.251 
Protein atoms 3714 
Ligands  1 
Water Molecules 141 
Unique Reflections 25715 
R.m.s.d.7  
   Bonds 0.01 
   Angles 1.14 
MolProbity Score8 1.59 
 Clash Score8 2.12 
RSCC9 0.94 
RSR9 0.21 
1Statistics for highest resolution bin of reflections in parentheses. 
2Rmerge =hj | Ihj-<Ih> | /hjIhj, where Ihj is the intensity of observation j of reflection h and <Ih> is the mean intensity for multiply recorded reflections. 
3Intensity signal-to-noise ratio. 
4Completeness of the unique diffraction data. 
5R-factor = h | IFoI – IFcI | / h|Fo|, where Fo and Fc are the observed and calculated structure factor amplitudes for reflection h. 
6Rfree is calculated against a 5% random sampling of the reflections that were removed before structure refinement.  
7Root mean square deviation of bond lengths and bond angles. 
8Chen et al. (2010) MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallographica D66:12-21. 
9wwPDB Validation Server. 
9wwPDB Validation Server. 
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Figure S3. Fo-Fc electron density map (dark gray grid contoured at 2.5 σ) created by omitting compound 10  and the side chain of C329, shows the presence of a 
covalent bond between the Sγ of C329 (yellow) and the second carbon of compound 10 ethyl group (green).  
Cellular Thermal Shift Assay 
Cellular thermal shift assays were employed to assess target engagement of compound 10 in live cells. MV4;11 or MOLM-13 cells 
were plated in 6-well plates at a density of 5 × 106 cells per well and treated for 1 h with compound 10 at concentrations ranging from 
0.4 to 300 nM. Cells were collected by centrifugation and washed with PBS. Cell pellets were resuspended in 100 μL of PBS containing 
Halt protease inhibitors, transferred to PCR tubes, and heated to 45 °C for 3 minutes. Cell lysis was achieved by two freeze-thaw cycles 
in liquid nitrogen. Lysates were clarified by centrifugation at 15,000 rpm. Supernatants were transferred to clean tubes, mixed with 
loading buffer, heated, and proteins were separated by SDS-PAGE. Membranes were blotted with anti-menin (CST, catalog # 6891) 
or anti-WDR5 antibodies (Santa Cruz biotechnology, sc-393080). 
Figure S4. Cellular thermal shift assay (CETSA) to assess the stabilization of cellular menin protein by compound 10 in MV4;11 and MOLM-13 cells. Cells were 
treated with compound 10 for 1 h and then were heated at 45 °C for 3 min, lysed, and the proteins separated by SDS-PAGE. Membranes were blotted with anti-
menin or anti-WDR5 antibody.   
Real-Time PCR 
Cells were treated with menin inhibitors at indicated concentrations, or with vehicle, giving a final concentration of 0.1% DMSO in all 
the samples. Total RNA was isolated from cells treated with various doses of the inhibitors at indicated treatment time, using the 
RNEASY kit (QIAGEN) according to the manufacturer’s protocol[9]. The cDNA was generated using a High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems). Real-time PCR amplifications of HOXA9, HOXA11, MEIS1, and GAPDH genes were carried 
out with primers specific for each gene, using TaqMan gene expression assays (Applied Biosystems). Relative quantification of each 
gene transcript was calculated by a comparative cycle threshold (Ct) method. The results were presented as relative expression to 
vehicle treatment after normalizing to an internal loading control GAPDH. 
 
 
 
C329
Covalent
Bond
Vehicle  300    100    33     11     3.7   1.23    0.4    300     100    33      11     3.7   1.23  0.4   Vehicle
WDR5
Menin
Compound 10 (nM) in MV4;11 cells Compound 10 (nM) in MOLM-13 cells
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Figure S5. a), b) Suppression of MEIS1 and HOXA gene expression by compound 10 in MV4;11cell lines. Cells were treated with different concentrations of 
compound 10 for 24 h or 6 h. c) Suppression of MEIS1 and HOXA gene expression by compound 10 in MOLM13 cell lines. Cells were treated with different 
concentrations of compound 10 for 24 h. mRNA levels of MEIS1, HOXA9 and HOXA11 were determined by RT-PCR. * (p <0.05), ** (p < 0.01). 
In vivo Pharmacodynamic Assay 
Female SCID mice were injected subcutaneously in the right flank with 5 million MV4;11 cells in a 5 mg/ml solution of Matrigel. When 
tumors reached 100-200 mm3, mice were injected with a single intravenous dose of either vehicle or compound 10 at 50 mg/kg. Tumors 
were harvested at 24 h or 48 h after the drug administration (3 per time point), immediately frozen in liquid nitrogen, ground into fine 
powder, placed on dry ice and stored at -80°C for analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S6. a), b) Pharmacodynamic effect of compound 10 on expression of MEIS1 and HOX genes in the MV4;11 xenograft tumor tissues.  Mice bearing MV4;11 
tumors were injected intravenously with a single dose of either vehicle or compound 10 at 50 mg/kg. Tumors were harvested 24 h or 48 h after the injection with 3 
tumors evaluated at each time point, and immediately frozen in liquid nitrogen, ground into fine powder, placed on dry ice and stored at -80 oC prior to RT-PCR 
analysis for expression levels of MEIS1, HOXA9 and HOXA11. * (p < 0.05); ** (p < 0.01). 
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General Chemistry Experiment and Information.  
Unless otherwise noted, commercial solvents and reagents were used without further purification with the following exception:  THF 
was freshly distilled from sodium wire. Proton nuclear magnetic resonance (1H NMR) and carbon nuclear magnetic resonance (13C 
NMR) spectra were recorded on a Bruker Advance 400 MHz spectrometer. 1H NMR spectra were reported in parts per million (ppm) 
downfield from tetramethylsilane (TMS). All 13C NMR spectra were reported in ppm and obtained with 1H decoupling. In reported 
spectral data, the format (δ) chemical shift (multiplicity, J values in Hz, integration) was used with the following abbreviations: s = singlet, 
d = doublet, t = triplet, q = quartet, m = multiplet. MS analyses were carried out with a Waters UPLC−mass spectrometer. The final 
compounds were all purified by C18 reverse phase preparative HPLC column with solvent A (0.1% TFA in H2O) and solvent B (0.1% 
TFA in MeCN) as eluents. The purity of all the final compounds was confirmed to be >95% by UPLC analysis (10% to 100% MeCN in 
H2O containing 0.1% CF3COOH in 10 min). The optical rotation was measured on Autopol® III automatic polarimetor (Rudolph Research 
Analytical). The specific optical rotation was calculated by application of the following formula: [α]DT = α / (l × c), where α is the observed 
angular rotation, l is the length of the cell in decimeters (l = 1 dm), c is the concentration in grams per milliliter (g/mL). 
Chemistry Experimental Procedures.  
Scheme 1: syntheses of compounds 2 and 3. 
 
 
Method A: synthesis of 2-(1-benzylpiperidin-4-yl)-2-phenylacetonitrile (20)[10] 
 
To a solution of 2-phenylacetonitrile (19) (10 g, 85.4 mmol) and 1-benzylpiperidin-4-one (16g, 85.4 mmol) in MeOH (200mL) was added 
MeONa (25% Wt. in MeOH, 23.4 mL, 102.4 mmol) under nitrogen, and the mixture was stirred under reflux overnight. Then, the reaction 
mixture was cooled to room temperature and concentrated to remove the solvent MeOH. The resulting mixture was dissolve in 
dichloromethane and poured into brine, and extracted with dichloromethane twice. The combined organic solution was dried over  
Na2SO4, filtered and the solvent was evaporated in vacuum. The crude intermediate was dissolved in MeOH (200 mL) and NaBH4 
(6.5g, 170.7 mmol) was added into the solution. The mixture was stirred at room temperature for 2 days. Then, the reaction mixture 
was concentrated, dissolved in dichloromethane and brine, and extracted with dichloromethane. Extract was dried over Na2SO4, filtered 
and concentrated in vacuum. The residue was purified by flash chromatography to obtain the title compound as a yellow solid (15g, 
61%). 1H NMR (400 MHz, CDCl3) δ 7.32-7.25 (m, 3H), 7.24-7.20 (m, 5H), 7.20-7.17 (m, 2H), 3.52 (d, J = 7.6 Hz, 1H), 3.43 (s, 2H), 
2.90-2.81 (m, 2H), 1.92-1.79 (m, 3H), 1.74-1.64 (m, 1H), 1.52-1.34 (m, 3H); ESI-MS calculated for C20H22N2 [M + H]+ = 291.18, found: 
291.19. 
 
2-(1-Benzylpiperidin-4-yl)-2-cyclopentyl-2-phenylacetonitrile (21) 
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To a solution of 2-(1-benzylpiperidin-4-yl)-2-phenylacetonitrile (20) (2g, 6.9 mmol) in dry THF (50 mL) was added dropwise LiHMDS 
(1M in THF, 13.8 mL, 13.8 mmol) at 0 oC under nitrogen. After stirring for 30 min, bromocyclopentane (0.89 mL, 8.3 mmol) was added 
dropwise and the reaction mixture was allowed to slowly warm to room temperature. After stirring overnight, the reaction was quenched 
with saturated NH4Cl, and concentrated to remove THF. The resulting mixture was extracted with dichloromethane twice, dried over 
Na2SO4, filtered and concentrated under vacuum.  The residue was purified by flash chromatography to obtain the title compound as a 
yellow solid (2 g, 81%). 1H NMR (400 MHz, CDCl3) δ 7.31-7.24 (m, 4H), 7.23-7.15 (m, 6H), 3.39 (s, 2H), 2.88-2.83 (m, 2H), 2.71-2.62 
(m, 1H), 1.96-1.78 (m, 5H), 1.70-1.64 (m, 1H), 1.58-1.49 (m, 4H), 1.46-1.41 (m, 2H), 1.26-1.11 (m, 3H).; ESI-MS calculated for C25H30N2 
[M + H]+ = 359.24, found: 359.32. 
 
Method B: synthesis of 2-cyclopentyl-2-phenyl-2-(piperidin-4-yl)acetonitrile (22) 
 
To a solution of the intermediate 21 (100 mg, 0.28 mmol) in methanol (5 mL) was added 10% Pd/C (30 mg). The mixture was stirred 
for 3 h at room temperature under hydrogen atmosphere (normal pressure). After the Pd/C catalyst was filtered off, the solvent was 
removed by rotary evaporation to give the title compound (74 mg, 99%). The product was used in the next step without further 
purification. 1H NMR (400 MHz, CDCl3) δ 7.32-7.26 (m, 4H), 7.24-7.20 (m, 1H), 3.06-3.02 (m, 2H), 2.72-2.63 (m, 1H), 2.60-2.46 (m, 
2H), 2.00-1.84 (m, 3H), 1.71-1.40 (m, 7H), 1.23-0.94 (m, 3H). ESI-MS calculated for C18H24N2 [M + H]+ = 269.19, found: 269.25. 
 
4-(3-Chloropropoxy)benzonitrile (23)[11] 
 
To a solution of 4-hydroxybenzonitrile (1.5 g, 12.6 mmol) and 1-bromo-3-chloropropane (2.2 g, 13.9 mmol) in acetonitrile was added 
K2CO3 (2.6 g, 18.9 mmol). The mixture was stirred at 80 oC. Then, the reaction mixture was cooled to room temperature and 
concentrated to remove the solvent acetonitrile. The resulting mixture was dissolve in dichloromethane and poured into brine,  and 
extracted with dichloromethane twice. The combined organic solution was dried over Na2SO4, filtered and the solvent was evaporated 
in vacuum. The residue was purified by flash chromatography to obtain the title compound as a white solid (1.5 g, 61%). 1H NMR (400 
MHz, CDCl3) δ 7.52 (d, J = 8.9 Hz, 2H), 6.89 (d, J = 8.9 Hz, 2H), 4.10 (t, J = 5.8 Hz, 2H), 3.68 (t, J = 6.2 Hz, 2H), 2.23-2.17 (m, 2H); 
ESI-MS calculated for C10H10ClNO [M + H]+ = 196.05, found: 196.18. 
 
Method C: synthesis of 4-(3-(4-(cyano(cyclopentyl)(phenyl)methyl)piperidin-1-yl)propoxy)benzonitrile (2) 
  
To a solution of the intermediate 22 (19 mg, 0.072 mmol) in acetonitrile (2 mL) was added 4-(3-chloropropoxy)benzonitrile (23) (16.8 
mg, 0.086 mmol), K2CO3 (20 mg, 0.11 mmol) and KI (1 mg, 0.007 mmol). The mixture was stirred at 80 °C overnight. Then, the mixture 
was extracted with ethyl acetate, washed with brine, dried over Na2SO4, and the solvent was evaporated under vacuum. The residue 
was purified by reverse phase preparative HPLC to give the title compound as a salt of trifluoroacetic acid (15 mg, 40%). 1H NMR (400 
MHz, MeOD) δ 7.65 (d, J = 9.0 Hz, 2H), 7.50-7.42 (m, 4H), 7.39-7.35 (m, 1H), 7.04 (d, J = 9.0 Hz, 2H), 4.13 (t, J = 5.8 Hz, 2H), 3.67-
3.59 (m, 2H), 3.27-3.22 (m, 2H), 3.11-2.98 (m, 2H), 2.97-2.89 (m, 1H), 2.44-2.37 (m, 1H), 2.32-2.27 (m, 1H), 2.22-2.15 (m, 2H), 2.08-
2.01 (m, 2H), 1.78-1.66 (m, 2H), 1.65-1.55 (m, 4H), 1.53-1.38 (m, 2H), 1.29-1.16 (m, 1H); 13C NMR (100 MHz, MeOD) δ 163.3, 136.0, 
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135.2, 129.8, 129.4, 129.2, 122.2, 119.9, 116.5, 105.3, 66.3, 57.3, 55.5, 53.6, 44.7, 41.5, 30.6, 30.0, 27.9, 26.5, 25.9, 25.8, 25.0; ESI-
MS calculated for C28H33N3O [M + H]+ = 428.26, found: 428.41; tR (UPLC) = 4.55 min; Purity > 99%. 
 
(1-(4-Cyanophenyl)azetidin-3-yl)methyl methanesulfonate (24) 
 
To a solution of 4-fluorobenzonitrile (2.6 g, 21.2 mmol) and azetidin-3-ylmethanol hydrochloride (3.4 g, 27.6 mmol) in DMSO was added 
K2CO3 (8.8 g, 63.7 mmol). The mixture was stirred at 80 °C overnight. Then, the reaction mixture was cooled to room temperature, 
pour into ice, and extracted with ethyl acetate twice. The combined organic solution was dried over Na2SO4, filtered and the solvent 
was evaporated in vacuum. The residue was dissolved in dichloromethane (100 mL) and Et3N (8.9 mL, 63.6 mmol) and methanesulfonyl 
chloride (2.5 mL, 31.8 mmol) were added dropwise successively at 0°C. The reaction mixture was allowed to warm to room temperature 
and stirred for 5 h. Then, the reaction mixture was quenched with saturated NaHCO3, and washed with brine, dried over Na2SO4, and 
the solvent was evaporated under vacuum. The residue was purified by flash chromatography to obtain the title compound as a white 
solid (2.5 g, 44%). 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.8 Hz, 2H), 6.31 (d, J = 8.8 Hz, 2H), 4.38 (d, J = 6.7 Hz, 2H), 4.02 (t, J = 
8.2 Hz, 2H), 3.74-3.70 (m, 2H), 3.16-3.08 (m, 1H), 2.99 (s, 3H); ESI-MS calculated for C12H14N2O3S [M + H]+ = 267.07, found: 267.11. 
 
4-(3-((4-(Cyano(cyclopentyl)(phenyl)methyl)piperidin-1-yl)methyl)azetidin-1-yl)benzonitrile (3) 
 
Method C using the intermediate 22 and 24. 1H NMR (400 MHz, MeOD) δ 7.50-7.42 (m, 6H), 7.40-7.36 (m, 1H), 6.46 (d, J = 8.8 Hz, 
2H), 4.16-4.12 (m, 2H), 3.72-3.69 (m, 2H), 3.54 (t, J = 14.1 Hz, 2H), 3.41 (d, J = 7.2 Hz, 2H), 3.24-3.16 (m, 1H), 3.12-2.98 (m, 2H), 
2.97-2.89 (m, 1H), 2.42-2.36 (m, 1H), 2.28 (d, J = 14.3 Hz, 1H), 2.08-2.00 (m, 2H), 1.76-1.67 (m 2H), 1.65-1.55 (m, 4H), 1.53-1.38 (m, 
2H), 1.29-1.16 (m, 1H); 13C NMR (100 MHz, MeOD) δ 154.8, 136.0, 134.4, 129.8, 129.5, 129.2, 122.2, 121.2, 112.0, 99.6, 60.9, 57.4, 
56.2, 53.6, 44.7, 41.4, 30.6, 30.0, 27.8, 26.7, 26.5, 25.9, 25.6; ESI-MS calculated for C29H34N4 [M + H]+ = 439.23, found: 439.42; tR 
(UPLC) = 4.53 min; Purity > 99%. 
 
Scheme 2: synthesis of compound 4. 
 
 
tert-Butyl ((1S,2S)-2-hydroxycyclopentyl)carbamate (26) 
 
To a solution of (1S,2S)-2-Aminocyclopentanol hydrochloride (25) (4.6 g, 33.7 mmol) and Et3N (9.4 mL, 67.4 mmol) in MeOH (50 mL) 
was added Boc2O (8.1 g, 37 mmol) at 0oC. The reaction was allowed to warm to room temperature and after overnight the reaction 
was concentrated and the crude was purified by column chromatography to give 26 as a white solid (6.5 g, 96%).1H NMR (400 MHz, 
CDCl3) δ 4.66 (s, 1H), 4.00-3.96 (m, 2H), 3.66-3.59 (m, 1H), 2.12-2.06 (m, 1H), 2.05-1.98 (m, 1H), 1.81-1.74 (m, 1H), 1.70-1.63 (m, 
2H), 1.45 (s, 9H), 1.38-1.31 (m, 1H). 
 
tert-Butyl 6-azabicyclo[3.1.0]hexane-6-carboxylate (27)[12] 
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To a solution of PPh3 (10.2 g, 38.8 mmol) in dry THF (100 mL) was added diisopropyl azodicarboxylate (7.84 g, 38.8 mmol) at -78oC. 
After stirring for 1h at -78oC, a solution of the intermediate 26 (6.5 g, 32.3 mmol) in dry THF (60 mL) was added dropwise. After overnight 
at room temperature, the reaction mixture was concentrated and then diluted with ethyl ether. The white precipitate was filtered off and 
the solvent was concentrated. The residue was purified by column chromatography to give the title compound 27 as oil (5.4 g, 91 %). 
1H NMR (400 MHz, CDCl3) δ 2.9 (s, 2H), 2.11-2.05 (m, 2H), 1.66-1.56 (m, 3H), 1.46 (s, 9H), 1.30-1.13 (m, 1H). 
 
Mixture of rac-tert-butyl ((1S,2R)-2-((S)-(1-benzylpiperidin-4-yl)(cyano)(phenyl)methyl)cyclopentyl)carbamate (28a) and rac-
tert-butyl ((1S,2R)-2-((R)-(1-benzylpiperidin-4-yl)(cyano)(phenyl)methyl)cyclopentyl)carbamate (28b) 
 
Compound 20 (1 g, 3.44 mmol), 18-Crown-6 (2.73 g, 10.33 mmol), and compound 27 (1.89 g, 10.33 mmol) were added to a dry round-
bottom flask. Then, the flask was covered with a kimwipe and dried in a desiccator under vacuum for 1-2 days.  After the drying step, 
the flask was removed from the desiccator and quickly capped with a septum. The system was vacuumed and protected under nitrogen 
atmosphere. The contents in the flask were then dissolved completely with 30 mL of freshly distilled THF. The solution was then briefly 
vacuumed then put under nitrogen atmosphere (This purging was repeated two more times). The reaction was cooled to -78 oC, KHMDS 
(0.5 M in toluene, 20.66 mL, 10.33 mmol) was added dropwise and then the reaction was allowed to warm to room temperature and 
stirred overnight.  After overnight, the reaction was quenched with saturated NH4Cl, extracted with ethyl acetate three times. The 
combined organic solvent was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatograph to 
give a 3:2 diastereomer mixture of 28a/28b as a white solid (1.1g, 67%). ESI-MS calculated for C30H39N3O2 [M + H]+ = 474.30, found: 
474.50. 
 
rac-Methyl ((1S,2R)-2-((S)-(1-benzylpiperidin-4-yl)(cyano)(phenyl)methyl)cyclopentyl)carbamate (29a) and rac-methyl ((1S,2R)-
2-((R)-(1-benzylpiperidin-4-yl)(cyano)(phenyl)methyl)cyclopentyl)carbamate (29b) 
 
To a solution of mixture 28a/28b (30 mg, 0.063 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (5 mL) at 0 oC. After 
stirring at room temperature for 1h, the reaction mixture was concentrated under vacuum, then basified with saturated NaHCO3, and 
extracted with dichloromethane three times. The combined organic solvent was dried over Na2SO4, filtered and concentrated under 
vacuum. The resulting residue was redissolved in dry dichloromethane (5 mL), and Et3N (0.018 mL, 0.129 mmol), dimethyl dicarbonate 
(10 mg, 0.077 mmol) were added at 0 oC. After stirring at room temperature for 1 h, the reaction mixture was quenched with H2O, and 
extracted with dichloromethane three times. The combined organic solvent was dried over Na2SO4, filtered and concentrated under 
vacuum. Then, the mixture 29a/29b were separated by reverse phase preparative HPLC to give the title compounds 29a (13 mg, 44%), 
and 29b (8 mg, 27%) as salts of trifluoroacetic acid. Date for 29a: 1H NMR (400 MHz, MeOD) δ 7.51-7.34 (m, 10H), 4.24 (s, 2H), 3.91-
3.86 (m, 1H), 3.53-3.46 (m, 2H), 3.43 (s, 3H), 3.06-2.96 (m,, 2H), 2.86-2.80 (m, 1H), 2.47 (t, J = 12.1 Hz, 1H), 2.26 (d, J = 14.4 Hz, 1H), 
2.13-2.07 (m, 1H), 1.90 (d, J = 14.4 Hz, 1H), 1.79-1.72 (m, 1H), 1.70-1.60 (m, 2H), 1.58-1.40 (m, 4H); ESI-MS calculated for C27H33N3O2 
[M + H]+ = 432.26, found: 432.53; tR (UPLC) = 3.31 min. Date for 29b: 1H NMR (400 MHz, MeOD) δ 7.48-7.41 (m, 9H), 7.39-7.35 (m, 
1H), 4.24 (s, 2H), 4.12-4.07 (m, 1H), 3.66 (s, 3H), 3.47 (t, J = 12.8 Hz, 2H), 3.11-3.04 (m, 1H), 2.93-2.87 (m, 1H), 2.81 (t, J = 11.3 Hz, 
1H), 2.55 (t, J = 12.1 Hz, 1H), 2.26 (d, J = 14.2 Hz, 1H), 2.00 (d, J = 14.4 Hz, 1H), 1.95-1.89 (m, 1H), 1.83-1.75 (m, 1H), 1.67-1.55 (m, 
3H), 1.44-1.34 (m, 2H), 1.30-1.21 (m, 1H); ESI-MS calculated for C27H33N3O2 [M + H]+ = 432.26, found: 432.51; tR (UPLC) = 3.82 min. 
 
rac-Methyl ((1S,2R)-2-((S)-cyano(1-((1-(4-cyanophenyl)azetidin-3-yl)methyl)piperidin-4-
yl)(phenyl)methyl)cyclopentyl)carbamate (4) 
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Compound 4 was synthesized using the method described for compound 2 from the intermediates 29a and 24. 1H NMR (400 MHz, 
MeOD) δ 7.52 (d, J = 7.2 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.45-7.36 (m, 3H), 6.47 (d, J = 8.8 Hz, 2H), 4.17-4.12 (m, 2H), 3.93-3.88 
(m, 1H), 3.73-3.70 (m, 2H), 3.60-3.51 (m, 2H), 3.44 (s, 3H), 3.42 (s, 2H), 3.23-3.17 (m, 1H), 3.07-2.99 (m, 2H), 2.89-2.83 (m, 1H), 2.50 
(t, J = 10.2 Hz, 1H), 2.28 (d, J = 14.6 Hz, 1H), 2.16-2.10 (m, 1H), 1.94 (d, J = 14.3 Hz, 1H), 1.79-1.44 (m, 7H); 13C NMR (100 MHz, 
MeOD) δ 158.2, 154.8, 134.4, 134.3, 129.7, 129.6, 122.0, 121.2, 112.0, 99.7, 61.0, 56.8, 56.2, 55.5, 53.6, 52.3, 40.7, 35.2, 30.1, 27.7, 
26.8, 26.1, 23.9; ESI-MS calculated for C31H37N5O2 [M + H]+ = 512.29, found: 512.42. tR (UPLC) = 3.65 min; Purity > 97%. 
 
Scheme 3: syntheses of compounds 6, 7, 8, 9 and 10 (The absolute stereochemistry of 15a was determined by X-ray crystallography, 
fluorine in green, oxygens in red, nitrogens in blue, carbons in gray, and hydrogens in light green, CDCC: 1581872) 
 
 
tert-Butyl ((1S,2R)-2-hydroxycyclopentyl)carbamate (31) 
 
To a solution of (1R,2S)-2-aminocyclopentanol hydrochloride (30) (11 g, 79.9 mmol) and Boc2O (20.9 g, 95.9 mmol) in dichloromethane 
(200 mL) was added dropwise Et3N (20.9 mL, 119.9 mmol) at 0 °C. The reaction mixture was allowed to warm to room temperature. 
After stirring overnight, the reaction mixture was washed with saturated brine and the water phase was extracted with dichloromethane 
twice. The combined organic solvent was dried over Na2SO4, filtered, and concentrated under vacuum. The residue was purified by 
flash column chromatography to give the intermediate 31 as oil (15.5 g, 96%). 1H NMR (400 MHz, CDCl3) δ 4.85 (s, 1H), 4.16 (s, 1H), 
3.80 (s, 1H), 2.02-1.95 (m, 1H), 1.93-1.87 (m, 1H), 1.86-1.77 (m, 2H), 1.70-1.65 (m, 1H), 1.59-1.51 (m, 2H), 1.45 (s, 9H). 
 
tert-Butyl (3aS,6aR)-tetrahydrocyclopenta[d][1,2,3]oxathiazole-3(3aH)-carboxylate 2-oxide (32) 
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To a solution of thionyl chloride (7 mL, 96.3 mmol) in dry acetonitrile (150 mL) was added a solution of the intermediate 31 (15.5g, 77.0 
mmol) in acetonitrile (150mL) at -35oC. Then, pyridine (18.7 mL, 231 mmol) was added dropwise and the reaction mixture was allowed 
to slowly warm to room temperature. After stirring overnight, the reaction mixture was concentrated, and water and ethyl acetate were 
added. The organic layer was separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic 
solvent was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography to produce the 
intermediate 32 as oil (18.8 g, 98%). 1H NMR (400 MHz, CDCl3) δ 5.74 (t, J = 4.6 Hz, 1H), 4.46 (s, 1H), 2.14-2.09 (m, 1H), 1.90-1.68 
(m, 5H), 1.52 (s, 9H).  
 
tert-Butyl (3aS,6aR)-tetrahydrocyclopenta[d][1,2,3]oxathiazole-3(3aH)-carboxylate 2,2-dioxide (14)[13] 
 
To a solution of the intermediate 32 (18.8 g, 76 mmol) in acetonitrile (100 mL) and H2O (100 mL) was added NaIO4 (24.4 g, 114 mmol) 
in portions, followed by addition of RuCl3.3H2O (315 mg, 1.5 mmol) at 0 °C. The reaction was stirred at room temperature for 2 hours.  
Then, the aqueous layer was extracted with diethyl ether three time. The combined organic solvent was dried over Na2SO4, filtered and 
concentrated. The residue was purified by column chromatography to produce the title compound 14 as a white solid (19 g, 95%). 1H 
NMR (400 MHz, CDCl3) δ 5.18-5.15 (m, 1H), 4.56-4.53 (m, 1H), 2.23-2.18 (m, 1H), 2.06-1.95 (m, 3H), 1.87-1.77 (m, 2H), 1.55 (s, 9H). 
ESI-MS calculated for C10H17NO5S [M + Na]+ = 286.07, found: 286.10. 
 
2-(1-Benzylpiperidin-4-yl)-2-(3-fluorophenyl)acetonitrile (13) 
 
Method A using 2-(3-fluorophenyl)acetonitrile (12) and 1-benzylpiperidin-4-one. 1H NMR (400 MHz, MeOD) δ 7.44-7.38 (m, 1H), 7.32-
7.28 (m, 4H), 7.27-7.22 (m, 1H), 7.18-7.16 (m, 1H), 7.13-7.05 (m, 2H), 3.98 (d, J = 7.1 Hz, 1H), 3.48 (s, 2H), 2.96-2.87 (m, 2H), 2.00-
1.92 (m, 2H), 1.87-1.80 (m, 1H), 1.79-1.72 (m, 1H), 1.59-1.52 (m, 1H), 1.50-1.39 (m, 2H); ESI-MS calculated for C20H21FN2 [M + H]+ = 
309.17, found: 309.16. 
 
tert-Butyl ((1S,2R)-2-((S)-(1-benzylpiperidin-4-yl)(cyano)(3-fluorophenyl)methyl)cyclopentyl)carbamate (15a) and tert-butyl 
((1S,2R)-2-((R)-(1-benzylpiperidin-4-yl)(cyano)(3-fluorophenyl)methyl)cyclopentyl)carbamate (15b) 
 
Compound 13 (2.18 g, 7.07 mmol), 18-Crown-6 (5.61 g, 21.21 mmol), and compound 14 (5.58 g, 21.21 mmol) were added to a dry 
round-bottom flask. Then, the flask was covered with a kimwipe and dried in a desiccator under vacuum for 1-2 days.  After the drying 
step, the flask was removed from the desiccator and quickly capped with a septum. The system was vacuumed and protected under 
nitrogen atmosphere. The contents in the flask were then dissolved completely with 60 mL of freshly distilled THF. The solution was 
then briefly vacuumed then put under nitrogen atmosphere (This purging was repeated two more times). The reaction was cooled to 0 
oC, KHMDS (0.5M in toluene, 42.4 mL, 21.21 mmol) was added dropwise and then the reaction was allowed to warm to room 
temperature and stirred overnight. After overnight, a solution of concentrated H2SO4 (0.6 mL, 11.31 mmol) in H2O (10 mL) was added 
(Note: PH of solution should be < 7) and the solution was vigorously stirred overnight. Then, the reaction mixture was slowly quenched 
and basified with saturated NaHCO3, extracted with ethyl acetate three times. The combined organic solvent was dried over Na2SO4, 
filtered and concentrated. The residue was purified by column chromatograph to give the mixture of diastereomers in a ratio of 3:2 as 
a yellow solid (2.5 g, 73%). Then, the diastereomers were separated by reverse phase preparative HPLC to give the enantiopure title 
compounds 15a (1.2 g, 36%) and 15b (0.8 g, 24%) as salts of trifluoroacetic acid, respectively. (Note: In large-scale synthesis, the 
enantiopure compound 15a can be isolated by recrystallization in a solution of hexane and dichloromethane with a ratio of 4:1). Date 
for 15a: 1H NMR (400 MHz, MeOD) δ 7.44-7.39 (m, 1H), 7.35 (d, J = 7.9 Hz, 1H), 7.31-7.22 (m, 6H), 7.11-7.06 (m, 1H), 3.82-3.77 (m, 
1H), 3.46 (s, 2H), 2.91 (t, J = 12.5 Hz, 2H), 2.81-2.76 (m, 1H), 2.07-1.93 (m, 5H), 1.80-1.72 (m, 1H), 1.62-1.46 (m, 5H), 1.33 (s, 9H), 
1.27-1.17 (m, 2H); ESI-MS calculated for C30H38FN3O2 [M + H]+ = 492.29, found: 492.36. [α]D20 = + 23.1, (c 1.17×10-3 g/mL, MeOH); tR 
(UPLC) = 4.46 min. Date for 15b: 1H NMR (400 MHz, MeOD) δ 7.50-7.43 (m, 6H), 7.27 (d, J = 7.3 Hz, 1H), 7.20 (d, J = 9.9 Hz, 1H), 
7.14 (t, J = 8.3 Hz, 1H), 4.24 (s, 2H), 4.02-3.98 (m, 1H), 3.54-3.45 (m, 2H), 3.08 (t, J = 11.4 Hz, 2H), 2.88-2.83 (m, 2H), 2.59 (t, J = 11.8 
Hz, 1H), 2.25 (d, J = 14.0 Hz, 1H), 1.99-1.87 (m, 2H), 1.79-1.74 (m, 1H), 1.67-1.57 (m, 3H), 1.46 (s, 9H), 1.43-1.37 (m, 2H), 1.33-1.18 
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(m, 1H); ESI-MS calculated for C30H38FN3O2 [M + H]+ = 492.29, found: 492.36. [α]D20 = + 9.4, (c 1.07 ×10-3 g/mL, MeOH); tR (UPLC) = 
4.63 min. 
 
Methyl ((1S,2R)-2-((S)-(1-benzylpiperidin-4-yl)(cyano)(3-fluorophenyl)methyl)cyclopentyl)carbamate (16a) 
 
To a solution of compound 15a as a salt of trifluoroacetic acid (1.2 g, 2.04 mmol) in dichloromethane (10 mL) was added trifluoroacetic 
acid (10 mL) at 0 oC. After stirring at room temperature for 3 h, the reaction mixture was concentrated under vacuum, then basified with 
saturated NaHCO3, and extracted with dichloromethane three times. The combined organic solvent was dried over Na2SO4, filtered 
and concentrated under vacuum. The resulting residue was redissolved in dry dichloromethane (50 mL), and Et3N (0.43 mL, 3.1 mmol), 
dimethyl dicarbonate (329 mg, 2.45 mmol) were added at 0 oC. After stirring at room temperature for 2h, the reaction mixture was 
quenched with H2O, and extracted with dichloromethane three times. The combined organic solvent was dried over Na2SO4, filtered 
and concentrated under vacuum. The residue was purified by flash column chromatograph to give the title compound 16a as a white 
solid (0.82 g, 89 %). 1H NMR (400 MHz, MeOD) δ 7.43-7.37 (m, 1H), 7.33-7.30 (m, 1H), 7.29-7.22 (m, 6H), 7.11-7.06 (m, 1H), 3.88-
3.83 (m, 1H), 3.46 (s, 2H), 3.43 (m, 3H), 2.91 (t, J = 11.0 Hz, 2H), 2.84-2.78 (m, 1H), 2.09-1.94 (m, 5H), 1.82-1.77 (m, 1H), 1.66-1.56 
(m, 3H), 1.55-1.48 (m, 2H), 1.39-1.29 (m, 1H), 1.26-1.16 (m, 1H); ESI-MS calculated for C27H32FN3O2 [M + H]+ = 450.25, found: 450.40. 
 
Methyl ((1S,2R)-2-((S)-(1-benzylpiperidin-4-yl)(cyano)(3-fluorophenyl)methyl)cyclopentyl)carbamate (17a) 
 
Method B using the intermediate 16a. 1H NMR (400 MHz, MeOD) δ 7.48-7.42 (m, 1H), 7.36 (d, J = 7.8 Hz, 1H), 7.27 (d, J = 10.5 Hz, 
1H), 7.16-7.11 (m, 1H), 3.91-3.85 (m, 1H), 3.44 (s, 3H), 3.41-3.37 (m, 2H), 3.00 (t, J = 12.4 Hz, 2H), 2.87-2.81 (m, 1H), 2.46 (t, J = 12.1 
Hz, 1H), 2.22 (d, J = 13.9 Hz, 1H), 2.15-2.12 (m, 1H), 1.90 (d, J = 13.8 Hz, 1H), 1.84-1.77 (m, 1H), 1.73-1.44 (m, 5H), 1.39-1.29 (m, 
1H); ESI-MS calculated for C20H26FN3O2 [M + H]+ = 360.20, found: 360.25. 
 
Methyl ((1S,2R)-2-((S)-cyano(1-((1-(4-cyanophenyl)azetidin-3-yl)methyl)piperidin-4-yl)(3-
fluorophenyl)methyl)cyclopentyl)carbamate (6) 
 
Method C using the intermediate 17a and 24. 1H NMR (400 MHz, MeOD) δ 7.50-7.43 (m, 3H), 7.36 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 
10.4 Hz, 1H), 7.17-7.13 (m, 1H), 6.47 (d, J = 8.8 Hz, 2H), 4.17-4.13 (m, 2H), 3.90-3.86 (m, 1H), 3.74-3.70 (m, 2H), 3.57 (t, J = 13.6 Hz, 
2H), 3.44 (s, 3H), 3.43-3.36 (m, 2H), 3.25-3.17 (m, 1H), 3.08-3.00 (m, 2H), 2.87-2.81 (m, 1H), 2.47 (t, J = 11.8 Hz, 1H), 2.27 (d, J = 
14.1 Hz, 1H), 2.16-2.13 (m, 1H), 1.97 (d, J = 14.6 Hz, 1H), 1.84-1.78 (m, 1H), 1.74-1.51 (m, 5H), 1.48-1.39 (m, 1H); 13C NMR (100 MHz, 
MeOD) δ 165.2, 162.8, 158.1, 154.8, 137.2, 137.1, 134.4, 131.5, 131.4, 125.6, 121.6, 121.2, 116.5, 116.3, 112.0, 99.8, 61.0, 56.8, 
56.1, 55.7, 53.6, 52.3, 40.9, 35.0, 30.0, 27.6, 26.7, 25.8, 23.8; ESI-MS calculated for C31H36FN5O2 [M + H]+ = 530.29, found: 530.32; tR 
(UPLC) = 3.75 min; Purity > 99%. [α]D20 = +1.5, (c 1.83 ×10-3 g/mL, MeOH). 
 
Method D: synthesis of (1-(4-(cyclobutylsulfonyl)phenyl)azetidin-3-yl)methyl methanesulfonate (37) 
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To a solution of 4-fluorobenzenethiol (33) (1 g, 7.8 mmol) in DMSO (10 mL) was added sodium tert-butoxide (1.12 g, 11.7 mmol) at 
room temperature. After stirring for 30 min at room temperature, bromocyclobutane (1.16 g, 8.6 mmol) was added. Then, the reaction 
mixture was heated to 80 oC and stirred overnight. The reaction mixture was cooled to room temperature and poured into water and 
dichloromethane. The layers were separated, and the aqueous layer was extracted with dichloromethane three times. The combined 
organic layers were washed with aqueous NaOH (1M, 3 x 20 mL) and brine, dried over Na2SO4, filtered and concentrated under vacuum 
to give crude sulfide intermediate 34. This intermediate was redissolved in dichloromethane (50 mL) and 3-Chloroperbenzoic acid (77% 
Wt., 3.49 g, 15.6 mmol) was added at 0 oC. Then the reaction mixture was allowed to warm to room temperature and stirred overnight. 
The reaction was quench with a solution of Na2S2O3 in water and washed with saturated NaHCO3. The organic layer was dried over 
Na2SO4, filtered and concentrated under vacuum. The residue was purified by column chromatography to give the intermediate 35 as 
a yellow solid (1.2 g, 72%). 1H NMR (400 MHz, CDCl3) δ 7.91-7.87 (m, 2H), 7.26-7.21(m, 2H), 3.83-3.75 (m, 1H), 2.61-2.51 (m, 2H), 
2.25-2.15 (m, 2H), 2.05-1.94 (m, 2H). 
To a solution of 35 (452 mg, 2.11 mmol) and azetidin-3-ylmethanol hydrochloride (287 mg, 2.32 mmol) in DMSO (5 mL) was added 
K2CO3 (875 mg, 6.33 mmol). The reaction mixture was heated to 80 oC and stirred overnight. The reaction mixture was cooled to room 
temperature and poured into water and dichloromethane. The layers were separated, and the aqueous layer was extracted with 
dichloromethane three times. The combined organic layers were dried over Na2SO4, filtered and concentrated under vacuum to give 
crude intermediate 36. This intermediate was redissolved in dichloromethane (20 mL), then Et3N (0.59 mL, 2.53 mmol) and 
methanesulfonyl chloride (0.20 mL, 2.53 mmol) were added at 0 oC. After stirring for 2h at room temperature, the reaction was quench 
with saturated NaHCO3 and extracted with dichloromethane three time. The combined organic layers was dried over Na2SO4, filtered 
and concentrated under vacuum. The residue was purified by column chromatography to give the title compound 37 as a yellow solid 
(455 mg, 60%). 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.8 Hz, 2H), 6.42 (d, J = 8.8 Hz, 2H), 4.46 (d, J = 6.7 Hz, 2H), 4.10 (t, J = 8.1 
Hz, 2H), 3.82-3.79 (m, 2H), 3.76-3.70 (m, 1H), 3.23-3.15 (m, 1H), 3.06 (s, 3H), 2.56-2.46 (m, 2H), 2.20-2.12 (m, 2H), 1.98-1.89 (m, 
2H); ESI-MS calculated for C15H21NO5S2 [M + H]+ = 360.09, found: 360.10. 
 
tert-Butyl 3-((4-(3-(((methylsulfonyl)oxy)methyl)azetidin-1-yl)phenyl)sulfonyl)azetidine-1-carboxylate (38) 
 
Method D using 4-fluorobenzenethiol and tert-butyl 3-bromoazetidine-1-carboxylate. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 8.9 Hz, 
2H), 6.43 (d, J = 8.8 Hz, 2H), 4.45 (d, J = 6.6 Hz, 2H), 4.23-4.19 (m, 2H), 4.12 (t, J = 8.2 Hz, 2H), 4.03 (t, J = 8.6 Hz, 2H), 3.92-3.87 
(m, 1H), 3.85-3.81 (m, 2H), 3.25-3.16 (m, 1H), 3.06 (s, 3H), 1.42 (s, 9H); ESI-MS calculated for C19H28N2O7S2 [M + Na]+ = 483.12, 
found: 483.22.  
 
Methyl ((1S,2R)-2-((S)-cyano(1-((1-(4-(cyclobutylsulfonyl)phenyl)azetidin-3-yl)methyl)piperidin-4-yl)(3-
fluorophenyl)methyl)cyclopentyl)carbamate (7) 
 
Method C using intermediate 17a and compound 37. 1H NMR (400 MHz, MeOD) δ 7.62 (d, J = 8.8 Hz, 2H), 7.48-7.42 (m, 1H), 7.35 (d, 
J = 7.6 Hz, 1H), 7.26 (d, J = 10.4 Hz, 1H), 7.17-7.12 (m, 1H), 6.51 (d, J = 8.8 Hz, 2H), 4.18-4.13 (m, 2H), 3.91-3.82 (m, 2H), 3.75-3.71 
(m, 2H), 3.57 (t, J = 13.1 Hz, 2H), 3.43 (s, 3H), 3.42-3.35 (m, 2H), 3.24-3.18 (m, 1H), 3.08-3.03 (m, 2H), 2.87-2.82 (m, 1H), 2.49-2.35 
(m, 3H), 2.26 (d, J = 14.5 Hz, 1H), 2.19-2.10 (m, 3H), 2.05-1.88 (m, 3H), 1.86-1.78 (m, 1H), 1.74-1.51 (m, 5H), 1.47-1.38 (m, 1H); 13C 
NMR (100 MHz, MeOD) δ 165.2, 162.8, 158.0, 155.7, 137.1, 131.5, 131.4, 130.9, 125.5, 121.6, 116.5, 116.3, 111.5, 61.0, 58.4, 56.8, 
56.2, 55.8, 53.6, 52.3, 41.0, 35.0, 30.0, 27.6, 26.8, 25.8, 23.8, 17.4; ESI-MS calculated for C34H43FN4O4S [M + H]+ = 623.30, found: 
623.38; tR (UPLC) = 3.92 min; Purity > 99%. [α]D20 = -34.8, (c 2.57 ×10-3 g/mL, MeOH). 
 
Methyl ((1S,2R)-2-((S)-(1-((1-(4-((1-acryloylazetidin-3-yl)sulfonyl)phenyl)azetidin-3-yl)methyl)piperidin-4-yl)(cyano)(3-
fluorophenyl)methyl)cyclopentyl)carbamate (8) 
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To a solution of the intermediate 17a (45 mg, 0.125 mmol) in acetonitrile (2 mL) was added compound 38 (58 mg, 0.125 mmol), K2CO3 
(35 mg, 0.25 mmol) and KI (2 mg, 0.013 mmol). The mixture was stirred at 80 °C overnight. Then, the mixture was extracted with ethyl 
acetate, washed with brine, dried over Na2SO4, and the solvent was evaporated under vacuum. The residue was purified by reverse 
phase preparative HPLC to give the salt of 18a. Compound 18a was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (5 
mL) was added at 0 °C. After stirring for 15 min at room temperature, the reaction mixture was concentrated under vacuum, basified 
with saturated NaHCO3, extracted with dichloromethane three times. The combined organic layers were dried over Na2SO4, filtered 
and concentrated under vacuum. The resulting residue was redissolved in dry dichloromethane (2 mL). Then, DIPEA (0.043 mL, 0.247 
mmol) and acryloyl chloride (0.020 mL, 0.247 mmol) were added at 0 °C. After stirring for 2 h at room temperature, the reaction mixture 
was concentrated under vacuum. The residue was purified by reverse phase preparative HPLC to give the title compound as a salt of 
trifluoroacetic acid (40 mg, 48%). 1H NMR (400 MHz, MeOD) δ 7.71 (d, J = 8.9 Hz, 2H), 7.48-7.43 (m, 1H), 7.35 (d, J = 7.8 Hz, 1H), 
7.26 (d, J = 10.4 Hz, 1H), 7.17-7.13 (m, 1H), 6.85 (d, J = 9.0 Hz, 1H), 6.54 (d, J = 8.9 Hz, 2H), 6.33-6.20 (m, 2H), 5.75 (dd, J = 2.7, 9.4 
Hz, 1H), 4.51-4.44 (m, 2H), 4.26-4.16 (m, 5H), 3.92-3.88 (m, 1H), 3.78-3.74 (m, 2H), 3.57 (t, J = 13.2 Hz, 2H), 3.44 (s, 3H), 3.45-3.36 
(m, 2H), 3.25-3.19 (m, 1H), 3.08-3.01 (m, 2H), 2.87-2.81 (m, 1H), 2.47 (t,  J = 11.9 Hz, 1H), 2.27 (d, J = 13.9 Hz, 1H), 2.16-2.13 (m, 
1H), 1.97 (d, J = 14.0 Hz, 1H), 1.84-1.78 (m, 1H), 1.74-1.53 (m, 5H), 1.48-1.39 (m, 1H); 13C NMR (100 MHz, MeOD) δ 167.6, 165.2, 
162.8, 162.3, 161.9, 158.1, 156.0, 137.2, 137.1, 131.5, 131.4, 128.8, 126.6, 125.6, 124.0, 121.6, 116.5, 116.3, 111.6, 60.9, 56.8, 56.1, 
55.8, 53.6, 52.3, 52.0, 50.0, 35.0, 30.0, 27.6, 26.7, 25.8, 23.8; ESI-MS calculated for C36H44FN5O5S [M + H]+ = 678.30, found: 678.40; 
tR (UPLC) = 3.43 min; Purity > 99%. [α]D20 = - 2.2, (c 1.07 ×10-3 g/mL, MeOH). 
 
Methyl ((1S,2R)-2-((S)-cyano(3-fluorophenyl)(1-((1-(4-((1-propionylazetidin-3-yl)sulfonyl)phenyl)azetidin-3-
yl)methyl)piperidin-4-yl)methyl)cyclopentyl)carbamate 
 (9) 
 
Compound 9 was synthesized using the method described for compound 8 from the intermediate 17a and propionic anhydride.1H NMR 
(400 MHz, MeOD) δ 7.71 (d, J = 8.8 Hz, 2H), 7.48-7.43 (m, 1H), 7.35 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 10.4 Hz, 1H), 7.17-7.13 (m, 1H), 
6.54 (d, J = 8.9 Hz, 2H), 4.41-4.34 (m, 2H), 4.21-4.15 (m, 3H), 4.09-4.07 (m, 2H), 3.91-3.86 (m, 1H), 3.78-3.74 (m, 2H), 3.57 (t, J = 
14.4 Hz, 2H), 3.44 (s, 3H), 3.45-3.36 (m, 2H), 3.25-3.19 (m, 1H), 3.08-3.00 (m, 2H), 2.87-2.81 (m, 1H), 2.47 (t, J = 12.1 Hz, 1H), 2.27 
(d, J = 13.5 Hz, 1H), 2.16-2.09 (m, 3H), 1.97 (d, J = 13.7 Hz, 1H), 1.84-1.78 (m, 1H), 1.74-1.53 (m, 5H),  1.48-1.39 (m, 1H), 1.05 (t, J 
= 7.5 Hz, 3H); 13C NMR (100 MHz, MeOD) δ 176.4, 165.2, 162.8, 158.1, 156.0, 137.2, 137.1, 131.6, 131.5, 131.4, 125.6, 124.1, 121.6, 
116.5, 116.3, 111.6, 60.9, 56.8, 56.1, 55.7, 53.6, 52.3, 52.2, 51.7, 50.0, 35.0, 30.0, 27.6, 26.7, 25.9, 25.2, 23.8, 9.0; ESI-MS calculated 
for C36H46FN5O5S [M + H]+ = 680.32, found: 680.43; tR (UPLC) = 3.40 min; Purity > 99%. [α]D20 = -0.6, (c 1.7 ×10-3 g/mL, MeOH). 
 
Methyl ((1S,2R)-2-((S)-cyano(1-((1-(4-((1-((E)-4-(dimethylamino)but-2-enoyl)azetidin-3-yl)sulfonyl)phenyl)azetidin-3-
yl)methyl)piperidin-4-yl)(3-fluorophenyl)methyl)cyclopentyl)carbamate (10) 
 
 
Compound 10 was synthesized using the method described for compound 8 from the intermediate 17a and (2E)-4-(dimethylamino)but-
2-enoyl chloride hydrochloride. 1H NMR (400 MHz, MeOD) δ 7.70 (d, J = 8.9 Hz, 2H), 7.48-7.42 (m, 1H), 7.34 (d, J = 7.8 Hz, 1H), 7.26 
(d, J = 10.5 Hz, 1H), 7.16-7.12 (m, 1H), 6.77-6.70 (m, 1H), 6.54 (d, J = 8.9 Hz, 2H), 6.47 (d, J = 15.3 Hz, 1H), 4.52 (d, J = 6.3 Hz, 2H), 
4.29-4.16 (m, 5H), 3.95-3.93 (m, 2H), 3.90-3.85 (m, 1H), 3.78-3.74 (m, 2H), 3.57 (t, J = 13.0 Hz, 2H), 3.45-3.35 (m, 2H), 3.43 (s, 3H), 
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3.27-3.22 (m, 1H), 3.07-3.01 (m, 2H), 2.90 (s, 6H), 2.87-2.82 (m, 1H), 2.46 (t, J = 11.7 Hz, 1H), 2.30 (d, J = 14.5 Hz, 1H), 2.16-2.13 (m, 
1H), 1.97 (d, J = 15.2 Hz, 1H), 1.85-1.78 (m, 1H), 1.74-1.53 (m, 5H), 1.48-1.38 (m, 1H); 13C NMR (100 MHz, MeOD) δ 165.8, 165.2, 
162.7, 158.0, 137.1, 133.0, 131.6, 131.5, 131.4, 131.3, 128.4, 125.6, 124.1, 121.6, 116.5, 116.2, 111.6, 60.9, 58.7, 56.8, 56.1, 55.8, 
53.6, 52.3, 52.2, 51.8, 50.2, 43.3, 41.0, 35.0, 30.0, 27.6, 26.7, 25.8, 23.8; ESI-MS calculated for C31H37N5O2 [M + H]+ = 735.36, found: 
735.40. tR (UPLC) = 2.91 min; Purity = 98%. [α]D20 = -1.4, (c 2.47 ×10-3 g/mL, MeOH). 
 
Methyl ((1S,2R)-2-((S)-cyano(1-((1-(4-cyanophenyl)azetidin-3-yl)methyl)piperidin-4-yl)(phenyl)methyl)cyclopentyl)carbamate 
(5) 
 
Compound 5 was synthesized using the method described for compound 6 from the intermediate 20 and 14. 1H NMR (400 MHz, MeOD) 
δ 7.52 (d, J = 7.2 Hz, 2H), 7.47 (d, J = 8.8 Hz, 2H), 7.45-7.36 (m, 3H), 6.47 (d, J = 8.8 Hz, 2H), 4.17-4.12 (m, 2H), 3.93-3.88 (m, 1H), 
3.73-3.70 (m, 2H), 3.60-3.52 (m, 2H), 3.44 (s, 3H), 3.42 (s, 2H), 3.23-3.17 (m, 1H), 3.07-2.99 (m, 2H), 2.89-2.83 (m, 1H), 2.50 (t, J = 
12.4 Hz, 1H), 2.28 (d, J = 13.9 Hz, 1H), 2.16-2.10 (m, 1H), 1.94 (d, J = 13.5 Hz, 1H), 1.79-1.44 (m, 7H); 13C NMR (100 MHz, MeOD) δ 
158.1, 154.8, 134.4, 134.3, 129.7, 129.6, 122.0, 121.2, 112.0, 99.7, 61.0, 56.8, 56.1, 55.6, 53.6, 52.3, 40.7, 35.2, 30.1, 27.6, 26.7, 26.0, 
23.9; ESI-MS calculated for C31H37N5O2 [M + H]+ = 512.29, found: 512.39. tR (UPLC) = 3.67 min; Purity > 99%. [α]D20 = +10.3, (c 1.6 
×10-3 g/mL, MeOH). 
 
Methyl ((1S,2R)-2-((R)-cyano(1-((1-(4-((1-((E)-4-(dimethylamino)but-2-enoyl)azetidin-3-yl)sulfonyl)phenyl)azetidin-3-
yl)methyl)piperidin-4-yl)(3-fluorophenyl)methyl)cyclopentyl)carbamate (11) 
   
Compound 11 was synthesized using the method described for compound 8 from the intermediate 15b and (2E)-4-(dimethylamino)but-
2-enoyl chloride hydrochloride. 1H NMR (400 MHz, MeOD) δ 7.70 (d, J = 8.8 Hz, 2H), 7.52-7.47 (m, 1H), 7.31 (d, J = 7.8 Hz, 1H), 7.25-
7.15 (m, 2H), 6.77-6.70 (m, 1H), 6.64 (d, J = 8.9 Hz, 2H), 6.48 (d, J = 15.3 Hz, 1H), 4.54-4.52 (m, 2H), 4.29-4.14 (m, 5H), 4.12-4.06 (m, 
1H), 3.95-3.93 (m, 2H), 3.79-3.74 (m, 2H), 3.69 (s, 3H), 3.58 (t, J = 13.6 Hz, 2H), 3.45 (d, J = 7.1 Hz, 2H), 3.26-3.19 (m, 1H), 3.14-3.08 
(m, 1H), 2.90 (s, 6H), 2.88-2.84 (m, 2H), 2.63 (t, J = 12.0 Hz, 1H), 2.30 (d, J = 14. 1Hz, 1H), 2.03-1.96 (m, 2H), 1.87-1.79 (m, 1H), 1.68-
1.59 (m, 3H), 1.51-1.42 (m, 2H), 1.32-1.23 (m, 1H); 13C NMR (100 MHz, MeOD) δ 165.8, 165.4, 162.9, 158.7, 156.0, 137.9, 137.8, 
133.0, 131.7, 131.6, 131.3, 128.4, 125.4, 124.0, 121.9, 116.6, 116.4, 111.6, 61.0, 58.7, 56.7, 56.1, 56.0, 55.8, 53.7, 52.7, 52.2, 51.9, 
50.2, 50.0, 43.3, 40.4, 35.6, 30.6, 27.6, 26.7, 26.0, 24.3; ESI-MS calculated for C31H37N5O2 [M + H]+ = 735.36, found: 735.45. tR (UPLC) 
= 3.32 min; Purity > 99%. [α]D20 = + 5.1, (c 2.4 ×10-3 g/mL, MeOH). 
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NMR Spectra 
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Single Crystal Structure of Compound 15a 
 
Figure S7. Single Crystal structure of compound 15a (Fluorine in green, oxygens in red, nitrogens in blue, carbons in gray, and hydrogens in light green, CDCC: 
1581872). 
Colorless needles of 15a were grown from a methanol solution of the compound at 22 C. A crystal of dimensions 0.26 × 0.04 × 0.04 
mm was mounted on a Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low temperature device and 
Micromax-007HF Cu-target micro-focus rotating anode ( = 1.54187 Å) operated at 1.2 kW power (40 kV, 30 mA). The X-ray intensities 
were measured at 85(1) K with the detector placed at a distance 42.00 mm from the crystal.  A total of 2028 images were collected with 
an oscillation width of 1.0 in . The exposure times were 1 sec. for the low angle images, 3 sec. for high angle.  Rigaku d*trek images 
were exported to CrysAlisPro for processing and corrected for absorption. The integration of the data yielded a total of 41135 reflections 
to a maximum 2 value of 139.82 of which 4942 were independent and 4792 were greater than 2(I). The final cell constants (Table 
S3) were based on the xyz centroids of 18755 reflections above 10(I). Analysis of the data showed negligible decay during data 
collection. The structure was solved and refined with the Bruker SHELXTL (version 2016/6) software package, using the space group 
P2(1)2(1)2(1) with Z = 4 for the formula C30H38N3O2F. All non-hydrogen atoms were refined anisotropically with the hydrogen atoms 
placed in a combination of idealized and refined positions. The o-fluorine atom of the terminal aryl group is disordered (50/50) over two 
sites related by 180 rotation of the ligand around the C11-C24 bond. Full matrix least-squares refinement based on F2 converged at 
R1 = 0.0371 and wR2 = 0.0900 [based on I > 2sigma(I)], R1 = 0.0389 and wR2 = 0.0944 for all data. Additional details are presented 
in Table S3 and are given as Supporting Information in a CIF file. 
Table S3. Sample and crystal data for 15a. 
Identification code 15a 
Empirical formula C30H38FN3O2 
Formula weight 491.63 g/mol 
Temperature 85(2) K 
Wavelength 1.54184 Å 
Crystal system, space group Orthorhombic,  P2(1)2(1)2(1) 
Unit cell dimensions a = 9.76750(10) Å α = 90° 
 b = 14.6292(2) Å β = 90° 
 c = 18.6690(3) Å γ = 90° 
Volume 2667.63(6) Å3 
Z, Density (calculated) 4, 1.224 g/cm3 
Absorption coefficient 0.652 mm-1 
F(000) 1056 
Crystal size 0.260 × 0.040 × 0.040 mm 
Thera range for data collection 3.839° to 69.909° 
Limiting indices -11<=h<=11, -17<=k<=17, -21<=l<=19 
Reflections collected / unique 41135 / 4942 [R(int) = 0.0581] 
Completeness to theta = 67.684 99.6 % 
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Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.82570 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4942 / 0 / 343 
Goodness-of-fit on F2 1.043 
Final R indices [I>2sigma(I)] R1 = 0.0371, wR2 = 0.0899 
R indices (all data) R1 = 0.0389, wR2 = 0.0943 
Extinction coefficient 0.0023(3) 
Largest diff. peak and hole 0.195 and -0.183 eÅ-3 
G.M. Sheldrick (2015) "Crystal structure refinement with SHELXL", Acta Cryst., C71, 3-8 (Open Access). 
CrystalClear Expert 2.0 r16, Rigaku Americas and Rigaku Corporation (2014), Rigaku Americas, 9009, TX, USA 77381-5209, Rigaku Tokyo, 196-8666, Japan. 
CrysAlisPro 1.171.38.41 (Rigaku Oxford Diffraction, 2015). 
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